INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo MIXOGEN® (injection)

RU M1800.031.002

SCHEDULING STATUS:
S5

PROPRIETARY NAME
(and dosage form):

MIXOGEN® (injection)

COMPOSITION
Each mL contains:
estradiol benzoate 1 mg
estradiol phenylpropionate 4 mg
testosterone propionate 20 mg
testosterone phenylpropionate 40 mg
testosterone isocaproate 40 mg
benzyl alcohol 10% v/v

PHARMACOLOGICAL CLASSIFICATION
A/21.9/ Androgen-estrogen combinations

PHARMACOLOGICAL ACTION
Mixogen is a balanced combination of oestradiol esters and testosterone esters, some with short and some with prolonged action.

INDICATIONS
Estrogen deficiency symptoms associated with the natural or surgical menopause.

CONTRA-INDICATIONS
- Pregnancy.
- Cardiovascular or Cerebrovascular disorders, e.g. thrombophlebitis, thrombo-embolic processes or a history of these conditions.
- Hypertension.
- Severe migraine.
- Liver disorders; cholestatic jaundice; a history of jaundice of pregnancy or jaundice due to estrogen/androgen use; Rotor syndrome and Dubin-Johnson syndrome.
- Known or suspected estrogen-dependant tumours.
- Endometrial hyperplasia.
- Undiagnosed vaginal bleeding.
- Haemoglobinopathies, e.g. sickle cell anaemia.
- Porphyria.
- Hyperlipoproteinaemia, especially in the presence of other risk factors predisposing to cardiovascular disorders.
- A history during pregnancy or previous estrogen use of severe pruritus, herpes gestationis or a deterioration of otosclerosis.

WARNINGS
If any signs of thrombo-embolic processes occur, treatment should be discontinued immediately.
In patients using estrogen-containing preparations, the risk of deep-vein thrombosis may be increased when undergoing major surgery or prolonged immobilisation.

DOSAGE AND DIRECTIONS FOR USE
Climacteric symptoms: 1 injection of 1 mL every 3 to 4 weeks or with longer intervals, depending on the clinical need.
Mixogen should be administered by deep intramuscular injection.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS
The following adverse reactions have been associated with either estrogen or androgen therapy or both:
- Genito-urinary tract
  intermenstrual bleeding, endometrial proliferation, excessive production of cervical mucous, increase in size of uterine fibromyomata, aggravation of endometriosis, enlarged clitoris.
- Breast
  tenderness, pain, enlargement, secretion.
- Gastro-intestinal tract
  nausea, vomiting, cholelithiasis, cholestatic jaundice.
- Cardiovascular system
  thrombosis, rise of blood pressure.
- Skin
  erythema nodosum, rash, oily skin, acne, hirsutism.
- Eyes
  discomfort of the cornea if contact lenses are used.
- Central nervous system
  headache, migraine, mood changes.
- Various
  water and salt retention, reduced glucose tolerance, change in body mass, hoarseness or deepening of the voice.
Case reports have been published of benign hepatic tumours.

Precautions
In the presence of severe varicose veins the benefits of estrogen therapy must be weighed against the possible risks.
Treatment should be discontinued if the results of liver function tests become abnormal or cholestatic jaundice appears.
There are reports indicating an association between the use of estrogen-containing preparations and the occurrence of cholelithiasis.
Pain in the breasts or excessive production of cervical mucous may be indicative of too high a dosage.
If early signs of virilisation occur, e.g. hoarseness of the voice, treatment should be discontinued.
The use of estrogen/androgen preparations may influence the results of certain laboratory tests.
During prolonged treatment with estrogens/androgens, periodic medical examinations are advisable.

Patients with the following conditions should be monitored:
- latent or overt cardiac failure, renal dysfunction, epilepsy or migraine (or a history of these conditions), since estrogens/androgens may induce salt and water retention;
- a history of hypertension; if hypertension develops, treatment should be discontinued;
- sickle cell trait, since in special conditions, e.g. during infections or anoxia, estrogens may induce
- thrombo-embolic processes;
- diabetes, since estrogens/androgens may influence the glucose tolerance and change the need for insulin or other antidiabetic medicines;
- oestrogen-sensitive gynaecological disorders, e.g. uterine fibromyomata that may increase in size, and endometriosis which may be aggravated by estrogen treatment.
The efficacy of Mixogen may be decreased by the concomitant administration of medicines such as the
anti-epileptic agents and rifampicin.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT
See ‘Side-effects and special precautions’.

CONDITIONS OF REGISTRATION
Advertising to the professions only.

IDENTIFICATION
A clear, oily solution in 1 mL ampoules marked in the neck with a red, a green and a yellow ring.

PRESENTATION
Boxes of 6 x 1 mL ampoules.

STORAGE INSTRUCTIONS
The ampoules should be protected from light and kept at temperatures below 30°C.
Keep out of reach of children.

REFERENCE NUMBER
G3190 (Act 101/1965)

NAME AND BUSINESS ADDRESS OF THE APPLICANT
Donmed Pharmaceuticals (Pty) Limited
Cambridge Place
cnr. Kirkby and Oxford Roads
Bedfordview 2007

DATE OF PUBLICATION OF THIS PACKAGE INSERT
1 May 1986

Under licence of N.V. Organon, The Netherlands

Packing number 34306.102

Updated on this site: March 2004
Source: Pharmaceutical Industry

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2004